Allakos/ALLK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Allakos

Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.

Ticker

ALLK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Alexander

Employees

131

Headquarters

San carlos, United States

Allakos Metrics

BasicAdvanced
$111M
Market cap
-
P/E ratio
-$2.45
EPS
0.91
Beta
-
Dividend rate
$111M
0.91422
$5.64
$0.98
506K
4.11
-81.27%
-111.56%
-92.78%
1.055
1.064
-1.16%

What the Analysts think about Allakos

Analyst Ratings

Majority rating from 9 analysts.
Hold

Allakos Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$71M
13.76%
Profit margin
0.00%
NaN%

Allakos Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 73.26%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.41
-$0.52
-$0.71
-$0.81
-
Expected
-$0.48
-$0.45
-$0.47
-$0.47
-$0.34
Surprise
-14.46%
14.99%
49.82%
73.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Allakos stock?

Allakos (ALLK) has a market cap of $111M as of June 18, 2024.

What is the P/E ratio for Allakos stock?

The price to earnings (P/E) ratio for Allakos (ALLK) stock is 0 as of June 18, 2024.

Does Allakos stock pay dividends?

No, Allakos (ALLK) stock does not pay dividends to its shareholders as of June 18, 2024.

When is the next Allakos dividend payment date?

Allakos (ALLK) stock does not pay dividends to its shareholders.

What is the beta indicator for Allakos?

Allakos (ALLK) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Allakos stock price target?

The target price for Allakos (ALLK) stock is $2.9, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Allakos stock

Buy or sell Allakos stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing